144 related articles for article (PubMed ID: 33887741)
1. Association between Dipeptidyl Peptidase-4 Inhibitor Prescription and Erythropoiesis-Stimulating Agent Hyporesponsiveness in Hemodialysis Patients with Diabetes Mellitus.
Hasegawa T; Zhao J; Bieber B; Zee J; Pisoni RL; Robinson BM; Hanafusa N; Nangaku M
Kidney Blood Press Res; 2021; 46(3):352-361. PubMed ID: 33887741
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin Hyporesponsiveness in Dialysis Patients: Possible Role of Statins.
Hasegawa T; Zhao J; Fuller DS; Bieber B; Zee J; Morgenstern H; Hanafusa N; Nangaku M
Am J Nephrol; 2017; 46(1):11-17. PubMed ID: 28564644
[TBL] [Abstract][Full Text] [Related]
3. Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients.
Rivara MB; Ikizler TA; Ellis CD; Mehrotra R; Himmelfarb J
BMC Nephrol; 2015 Jun; 16():79. PubMed ID: 26045064
[TBL] [Abstract][Full Text] [Related]
4. Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.
Bae MN; Kim SH; Kim YO; Jin DC; Song HC; Choi EJ; Kim YL; Kim YS; Kang SW; Kim NH; Yang CW; Kim YK
PLoS One; 2015; 10(11):e0143348. PubMed ID: 26588085
[TBL] [Abstract][Full Text] [Related]
5. Resistance to Erythropoiesis-Stimulating Agents in Pre-Dialysis and Post-Dialysis Mortality in Japanese Incident Hemodialysis Patients.
Hayashi T; Joki N; Tanaka Y; Iwasaki M; Kubo S; Matsukane A; Takahashi Y; Imamura Y; Hirahata K; Hase H
Blood Purif; 2019; 47 Suppl 2(Suppl 1):31-37. PubMed ID: 30943479
[TBL] [Abstract][Full Text] [Related]
6. Hyporesponsiveness to erythropoiesis-stimulating agent as a prognostic factor in Japanese hemodialysis patients: the Q-Cohort study.
Eriguchi R; Taniguchi M; Ninomiya T; Hirakata H; Fujimi S; Tsuruya K; Kitazono T
J Nephrol; 2015 Apr; 28(2):217-25. PubMed ID: 25080399
[TBL] [Abstract][Full Text] [Related]
7. Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient.
Goodkin DA; Zhao J; Cases A; Nangaku M; Karaboyas A
Am J Nephrol; 2022; 53(5):333-342. PubMed ID: 35462377
[TBL] [Abstract][Full Text] [Related]
8. Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D).
Macdougall IC; Meadowcroft AM; Blackorby A; Cizman B; Cobitz AR; Godoy S; Jha V; Johansen KL; McMahon G; Obrador GT; Wong MG; Singh AK
Am J Nephrol; 2023; 54(1-2):1-13. PubMed ID: 36739866
[TBL] [Abstract][Full Text] [Related]
9. Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients.
Rattanasompattikul M; Molnar MZ; Zaritsky JJ; Hatamizadeh P; Jing J; Norris KC; Kovesdy CP; Kalantar-Zadeh K
Nephrol Dial Transplant; 2013 Jul; 28(7):1936-45. PubMed ID: 23045431
[TBL] [Abstract][Full Text] [Related]
10. Not baseline but time-dependent erythropoiesis-stimulating agent responsiveness predicts cardiovascular disease in hemodialysis patients receiving epoetin beta pegol: A multicenter prospective PARAMOUNT-HD Study.
Fujii H; Hamano T; Tsuchiya K; Kuragano T; Joki N; Tsuruya K; Honda H; Uemura Y; Nitta K;
Int J Cardiol; 2023 Mar; 375():110-118. PubMed ID: 36592827
[TBL] [Abstract][Full Text] [Related]
11. Changes in erythropoiesis-stimulating agent responsiveness after transfer to combined therapy with peritoneal dialysis and hemodialysis for patients on peritoneal dialysis: A prospective multicenter study in Japan.
Maruyama Y; Yokoyama K; Higuchi C; Sanaka T; Tanaka Y; Sakai K; Kanno Y; Ryuzaki M; Sakurada T; Hosoya T; Nakayama M;
Ther Apher Dial; 2023 Aug; 27(4):735-741. PubMed ID: 36897071
[TBL] [Abstract][Full Text] [Related]
12. Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study.
Fuller DS; Robinson BM; Locatelli F; Pisoni RL
Nephron; 2018; 140(1):24-30. PubMed ID: 29945128
[TBL] [Abstract][Full Text] [Related]
13. Dynamics of the erythropoiesis stimulating agent resistance index in incident hemodiafiltration and high-flux hemodialysis patients.
Marcelli D; Bayh I; Merello JI; Ponce P; Heaton A; Kircelli F; Chazot C; Di Benedetto A; Marelli C; Ladanyi E; Kroczak M; Stuard S; Grassmann A; Scatizzi L; Brand K; Canaud B
Kidney Int; 2016 Jul; 90(1):192-202. PubMed ID: 27178833
[TBL] [Abstract][Full Text] [Related]
14. Time-dependent resistance to erythropoiesis-stimulating agent and mortality in hemodialysis patients in the Japan Dialysis Outcomes and Practice Patterns Study.
Fujikawa T; Ikeda Y; Fukuhara S; Akiba T; Akizawa T; Kurokawa K; Saito A
Nephron Clin Pract; 2012; 122(1-2):24-32. PubMed ID: 23486237
[TBL] [Abstract][Full Text] [Related]
15. Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients.
Luo J; Jensen DE; Maroni BJ; Brunelli SM
Am J Kidney Dis; 2016 Nov; 68(5):763-771. PubMed ID: 27528373
[TBL] [Abstract][Full Text] [Related]
16. Butyrylcholinesterase level as an independent factor of erythropoiesis-stimulating agent resistance in patients on maintenance hemodialysis: a single-center cross-sectional study.
Okamoto T; Hatakeyama S; Tanaka Y; Imanishi K; Takashima T; Saitoh F; Koie T; Suzuki T; Ohyama C
Clin Exp Nephrol; 2018 Oct; 22(5):1174-1181. PubMed ID: 29600410
[TBL] [Abstract][Full Text] [Related]
17. ESA Hyporesponsiveness Is Associated with Adverse Events in Maintenance Hemodialysis (MHD) Patients, But Not with Iron Storage.
Kuragano T; Kitamura K; Matsumura O; Matsuda A; Hara T; Kiyomoto H; Murata T; Fujimoto S; Hase H; Joki N; Fukatsu A; Inoue T; Itakura Y; Nakanishi T
PLoS One; 2016; 11(3):e0147328. PubMed ID: 26933949
[TBL] [Abstract][Full Text] [Related]
18. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
19. Association of plasma ortho-tyrosine/para-tyrosine ratio with responsiveness of erythropoiesis-stimulating agent in dialyzed patients.
Kun S; Mikolás E; Molnár GA; Sélley E; Laczy B; Csiky B; Kovács T; Wittmann I
Redox Rep; 2014 Sep; 19(5):190-8. PubMed ID: 24693974
[TBL] [Abstract][Full Text] [Related]
20. C-reactive protein but not hepcidin, NGAL and transferrin determines the ESA resistance in hemodialysis patients.
Yılmaz I; Ozkok A; Kostek O; Kolukısa A; Duran I; Odabaş AR; Kemal Işman F; Işbilen Başok B
Ren Fail; 2016; 38(1):89-95. PubMed ID: 26539647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
